Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the classic male presentation.

We recently published a list of Jim Cramer Put These 14 Stocks Under the Microscope. In this article, we are going to take a ...

In vivo platelet activation and related pathways may be linked to small airways disease and pulmonary vascular changes in smokers.

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of treatment.

Rationale Chronic obstructive pulmonary disease (COPD) is the most common indication for domiciliary non-invasive ventilation ...